Objective: To observe the effect of Yugan Granule (YGG) in treating patients of chronic hepatitis B infected with basic core promoter (BCP) mutant HBV.
Methods: BCP mutation was detected by microwell liquid hybridization combined with enzyme linked immunosorbent assay (ELISA) and 46 patients were confirmed to be the mutant positive (Group A), and 69 the mutant negative (Group B). All patients were treated by YGG and the clinical symptoms and laboratory parameters before and after treatment were observed.
Results: The scores of symptoms and serum levels of alanine transaminase (ALT) and total bilirubin (TBil) were decreased markedly in both groups after treatment. The HBeAg negative conversion rate in Group A was 60%, obviously higher than that in Group B (30%, P < 0.05), while HBV-DNA negative conversion rate between the two groups had the insignificant difference. The overall efficacy was similar in the two groups.
Conclusion: YGG could remarkably alleviate the symptoms, reduce serum levels of ALT and TBil, and showed the effect of anti-HBV with the same efficacy both to BCP mutant and wild strain HBV infected patients.
Download full-text PDF |
Source |
---|
Zhongguo Ying Yong Sheng Li Xue Za Zhi
September 2021
Gansu College of Traditional Chinese Medicine, Lanzhou 730000, China.
To investigate the therapeutic effects of Biejia Yugan Granule on hepatic fibrosis caused by compound factors in rats and its effect on TGF-β1/Smads signaling pathway. SD rats were randomly divided into blank control group, model control group, colchicine group, Biejia Yugan Granule low, medium and high dose (1.85, 3.
View Article and Find Full Text PDFZhongguo Ying Yong Sheng Li Xue Za Zhi
November 2020
Gansu College of Traditional Chinese Medicine, Lanzhou 730000, China.
To investigate the prevention and treatment effect of (BYG) on ethanol-induced hepatic fibrosis (EHF) rats. SD rats were randomly divided into blank control group, model group, BYG group, colchicine group and BYG low and BYG high dose groups (=8). The EHF rat model was established by intragastric edible ethanol with a gradually increased dose.
View Article and Find Full Text PDFZhongguo Ying Yong Sheng Li Xue Za Zhi
September 2020
Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000, China.
Zhongguo Zhong Xi Yi Jie He Za Zhi
July 2002
Second Affiliated Hospital to Luzhou Medical College, Sichuan 646000.
Objective: To observe the effect of Yugan Granule (YGG) in treating patients of chronic hepatitis B infected with basic core promoter (BCP) mutant HBV.
Methods: BCP mutation was detected by microwell liquid hybridization combined with enzyme linked immunosorbent assay (ELISA) and 46 patients were confirmed to be the mutant positive (Group A), and 69 the mutant negative (Group B). All patients were treated by YGG and the clinical symptoms and laboratory parameters before and after treatment were observed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!